SEC Form 4 · accession 0001415889-18-000118
MABVAX THERAPEUTICS HOLDINGS, INC. · MBVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas C Varvaro
Director
Period of report
Jan 23, 2018
Accepted (ET)
Jan 24, 2018 · 7:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001109196
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jan 23, 2018 | S | 17,445 | $0.87 | D | 85,641 | D | |
| Common StockF3 | Jan 24, 2018 | S | 17,996 | $0.84 | D | 67,645 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a portion of the number of shares required to be sold by the reporting person to cover estimated tax obligations in connection with the vesting of the RSUs of the reporting person. This sale is mandated by the Issuer's election, as approved by the Board of Directors, under the equity incentive plan to require satisfaction of estimated tax obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- F2The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.85 to $0.89 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.86 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.